Integra LifeSciences (IART) News Today

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) has earned an average recommendation of "Hold" from the nine research firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four hav

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 3,990,000 shares, a growth of 59.6% from the May 15th total of 2,500,000 shares. Based on an average trading volume of 1,120,000 shares, the days-to-cover ratio is presently 3.6 days. Approximately 6.0% of the shares of the stock are short sold.

Madison Avenue Partners LP boosted its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 8.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,042,156 shares of the life sciences company's stock a

Point72 Europe London LLP raised its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 54.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 719,663 shares of the life sciences company's stock a

Seven Eight Capital LP bought a new position in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 37,081 shares of the life sciences company's stock, valued at appr

The Manufacturers Life Insurance Company grew its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 36.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 715,294 s

Capital Research Global Investors raised its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 40.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,297,326 shares of the life

Campbell & CO Investment Adviser LLC acquired a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 35,693 shares of the life sciences company's stoc

Norges Bank bought a new stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 672,141 shares of the life sciences company's stock, valued at approximat

Dimensional Fund Advisors LP increased its position in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 4.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,615,112 shares of the life sciences company's stock after acquiring an a

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) Chairman Stuart Essig bought 52,641 shares of Integra LifeSciences stock in a transaction dated Thursday, May 23rd. The stock was acquired at an average cost of $28.49 per share, for a total transaction of $1,499,742.09. Following the purchase, the chairman now directly owns 487,922 shares in the company, valued at approximately $13,900,897.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Victory Capital Management Inc. cut its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 99.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,971 shares of the

Integra LifeSciences (NASDAQ:IART) Trading 4% Higher on Analyst Upgrade

Citigroup upped their price target on Integra LifeSciences from $24.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday.

Clearbridge Investments LLC lessened its position in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 9.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,474,249 shares of the life sciences company's stock af

GW&K Investment Management LLC trimmed its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 8.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 693,553

Integra LifeSciences (NASDAQ:IART) Sees Unusually-High Trading Volume

Morgan Stanley cut their price objective on Integra LifeSciences from $37.00 to $24.00 and set an "underweight" rating for the company in a research note on Tuesday.

Integra LifeSciences (NASDAQ:IART - Get Free Report) announced its quarterly earnings results on Monday. The life sciences company reported $0.55 EPS for the quarter, meeting the consensus estimate of $0.55. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The firm had revenue of $368.90 million for the quarter, compared to analyst estimates of $361.96 million. During the same quarter last year, the firm posted $0.74 earnings per share. The business's revenue for the quarter was down 3.2% on a year-over-year basis.

Oppenheimer cut shares of Integra LifeSciences from an "outperform" rating to a "market perform" rating in a report on Tuesday.

Integra LifeSciences (NASDAQ:IART) Reaches New 52-Week Low at $24.16

Integra LifeSciences (NASDAQ:IART) updated its FY24 earnings guidance. The company provided EPS guidance of $3.01-3.11 for the period, compared to the consensus estimate of $3.19. The company also issued revenue guidance of $1.67-1.69 billionillion, compared to the consensus estimate of $1.62 billionillion.

Integra LifeSciences (NASDAQ:IART) updated its second quarter earnings guidance. The company provided EPS guidance of $0.60-0.65 for the period, compared to the consensus estimate of $0.74. The company also issued revenue guidance of $411-416 millionillion, compared to the consensus estimate of $395.81 millionillion.

Fisher Asset Management LLC lowered its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 15.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 396,798 shares of the life sciences com

StockNews.com cut Integra LifeSciences from a "buy" rating to a "hold" rating in a report on Tuesday.

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 2,610,000 shares, an increase of 24.9% from the March 31st total of 2,090,000 shares. Approximately 4.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 725,500 shares, the short-interest ratio is presently 3.6 days.

Integra LifeSciences (NASDAQ:IART) Hits New 12-Month Low at $27.18